Publications

 
Publications in Peer Reviewed Journals

1. J. Newburger, A. Adjei and A. Martin, "A Simplified Method to Estimate Total Area Under the Blood-Plasma Concentration versus Time Curve" J. Clin. Pharmacol. 20(11,12):659 (1980).
 
2. A. Martin, J. Newburger and A. Adjei, "A New Solubility Equation", J. Pharm. Sci. 68, iv, October, 1979.
 
3. A. Martin, J. Newburger and A. Adjei, "Extended Hildebrand Solubility Approach: Solubility of Theophylline in Polar Binary Solvents", J. Pharm. Sci., 69:487 (1980).
 
4. A. Adjei, J. Newburger and A. Martin, "Extended Hildebrand Approach: Solubility of Caffeine in Dioxane-Water Mixtures", J. Pharm. Sci., 69:659 (1980).
 
5. A. Martin, A. Paruta and A. Adjei, "Extended Hildebrand Solubility Approach: Methyxanthines in Mixed Solvents", J. Pharm. Sci., 70:1115 (1981).
 
6. A. Martin, P. L. Wu, A. Adjei, A. Beerbower and J. M. Prausnitz, "Extended Hansen Solubility Approach: Naphthalene in Individual Solvents", J. Pharm. Sci., 70:1260 (1981).
 
7. A. Martin, P. L. Wu, A. Adjei, A. Beerbower, and J. M. Prausnitz, "Extended Hansen Solubility Approach and The Log Linear Solubility Equation," J. Pharm. Sci., 71:849 (1982).
 
8. A. Martin, P. L. Wu, A. Adjei, M. Mehdizadeh, K. C. James and Carl Metzler, "Extended Hildebrand Solubility Approach: Testosterone and Testosterone Propionate in Binary Solvents", J. Pharm. Sci., 71:1334 (1982).
 
9. A. Adjei, J. Newburger, S. Stavchansky, and A. Martin, "Membrane Solubility Parameter and In Situ Release of Theophylline", J. Pharm. Sci., 73:742 (1984).
 
10. A. Adjei, R. Doyle, E. Johnson, M. Pratt, and R. Finley, "Bioavailability of Leuprolide Following Intratracheal Administration to Beagle Dogs.", Int. J. Pharm. 61:135-144 (1990).
 
11. A. Adjei, and J. Garren, "Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers." Pharm. Res. 7(6):565-569 (1990).
 
12. A. Adjei, D. Lee, T. Reiland, "Bioavailability of Leuprolide Following Administration of Inhalation Aerosols to Beagle Dogs", J. Aerosol Med., 4 (Suppl. 1), P263, 1991 [Also presented by special invite at 8th Congress of the International Symposium For Aerosols in Medicine (ISAM), Davos Switzerland, April 14-17, 1991]
 
13. A. Adjei, D. Sundberg, J. Miller, A. Chun, "Bioavailability of Leuprolide Acetate Following Nasal and Inhalation Delivery to Rats and Healthy Humans", Pharm. Res., 9(2):244-249, 1992.
 
14. A. Adjei, J. Garren, G. Menon, S. Rao, M. Vadnere, "Effect of Ion-pairing on Octanol-Water Partitioning of Peptide Drugs I: The Nonapeptide Leuprolide Acetate", Int. J. Pharm. 90:141-149, 1993.
 
15. A. Adjei, S. Love, G. Diaz, J. Greer, F. Haviv, E. Bush, "Effect Of Formulation Adjuvants On Gastrointestinal Absorption Of Leuprolide Acetate", J. Drug Targeting, 1:251-258, 1993.
 
16. M. Fu Lu, D. Lee, R. Carlson, G. Subba Rao, H-W Hui, A. Adjei, M. Herrin, D. Sundberg, L. Hsu, "The effects of Formulation Variables on Iontophoretic Transdermal Delivery to Humans", Drug Del. and Ind. Pharm, 19(13):1557-1571, 1993.
 
17. A. Adjei, J. Hui, R. Finley, T. Lin, J. Lancaster, and F. Fort, "Pulmonary Bioavailability of Leuprolide Acetate Following Multiple Dosing to Beagle Dogs: Some Pharmacokinetic and Preclinical Issues". Int. J. Pharm. 107, 57-66, 1994 [Also presented by special invite at International Symposium of Aerosols in Medicine, Garnisch-Partenkirchen, Germany, March 30-April 3, 1993].
 
18. A. Adjei and P. Gupta, "Pulmonary Delivery of Therapeutic Peptides and Proteins", J. Controlled Release, 29:361-373, 1994 [Also presented by special invite at 4th International Symposium on Disposition and Delivery of Peptide Drugs, Center for Bio-Pharmaceutical Sciences (Control Release Society), April 22-25, 1993, Leiden, The Netherlands].
 
19. M. Powers, A. Adjei, M. FuLu, M. Manning, "Solution Behavior of Leuprolide Acetate, a LH-RH agonist, as Determined by Circular Dichroism Spectroscopy", Int. J. Pharm. 108:49-55, 1994.
 
20. Y. Qiu, P. Gupta, H. Cheskin, A. Adjei "Pulmonary Bioavailability and Absorption Characteristics of the 5-Lipoxygenase inhibitor, Abbott-79175, in Beagle Dogs". Int. J. Pharm., 115:95-102, 1995.  [Also presented at Mid West AAPS Meeting by abstract, chicago, May, 1994].
 
21. A. Annapragada and A. Adjei, "An Analysis of the Fraunhoffer Diffraction Method For Particle Size Distribution Analysis and Its Application to Aerosolized Sprays", Int. J. Pharm., 127:219-227, 1996.
 
22. A. Annapragada and A. Adjei, "Numerical Simulation of Milling Processes as an Aid to Process Design", Int. J. Pharm., 136(1-2): 1-11, 1996.
 
23. P. Gupta, J. Cannon and A. Adjei, “Liposomal Formulations of Abt-077: In Vitro Characterization Studies”, Int. J. Pharm. 140:119-129, 1996.
 
24. P. Swanson, F. Muzzio, A. Annapragada and A. Adjei, "Numerical Analysis of Motion and Deposition of Particles In Cacade Impactors", Int. J. Pharm., 142:33-51 (1996).
 
25. J. B. Cannon, L. A. Adjei, M. Y. Fu Lu, and K. Garren, “Alternate Drug Delivery Routes for A-71623, A Potent Cholecystokinin-A Receptor Agonist Tetrapeptide”, J. Drug Targeting, 4(2):69-78 (1996).
 
26. P. Gupta, Y. Qiu and A. Adjei, “Pulmonary Delivery of the 5-Lipoxygenase Inhibitor, Abbott-85761, in Beagle Dogs”, Int. J. Pharm., 147:207-218, 1997.
 
27. Yuqun Zheng, Kennan C. Marsh, Richard J. Bertz, Tawakol El-Shourbagy,
Pramod K. Gupta, and Akwete L. Adjei, “Pulmonary Delivery of a Dopamine D-1 Agonist, ABT-431, in Dogs and Humans”, Int. J. Pharm., 191:131-140 (1999).
 
28. Franklin W. Okumu, Rai -Yun Lee, James D. Blanchard, Anthony Queirolo, Christine M. Woods, Peter M. Lloyd, Jerry Okikawa, Igor Gonda, Stephen J. Farr, Reid Rubsamen, Akwete L. Adjei, and Richard J. Bertz. “Evaluation of the AERx Pulmonary Delivery System for Systemic Delivery of a Poor Soluble Selective D-1 Agonist, ABT-431”, Pharm. Res., 19 (7) 1010-1013, 2002.